PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification :	A2	(11) International Publication Number:	WO 99/08500
Not classified		(43) International Publication Date:	25 February 1999 (25.02.99)

(21) International Application Number: PCT/SE98/02028

(22) International Filing Date: 10 November 1998 (10.11.98)

(71) Applicant *(for all designated States except US)*: ASTRA AKTIEBOLAG [SE/SE]; S–151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: LÖVQVIST, Karin [SE/SE]; Astra Hässle AB, S–431 83 Mölndal (SE). NORELAND, David [SE/SE]; Astra Production Chemicals AB, S–151 85 Södertälje (SE). SUNDÉN, Gunnel [SE/SE]; Astra Hässle AB, S–431 83 Mölndal (SE). YMÉN, Ingvar [SE/SE]; Astra Production Chemicals AB, S–151 85 Södertälje (SE).

(74) Agent: ASTRA AKTIEBOLAG; Intellectual Property, Patents, S–151 85 Södertälje (SE).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

Upon the request of the applicant, before the expiration of the time limit referred to in Article 21(2)(a).
Without international search report and to be republished upon receipt of that report.
Without classification; title and abstract not checked by the International Searching Authority.

(54) Title: NEW CRYSTALLINE FORM OF OMEPRAZOLE

(57) Abstract

The present invention relates to a novel crystalline form of 5–methoxy–2–[[(4–methoxy–3,5–dimethyl– 2–pyridinyl)methyl] sulfinyl]–1H– benzimidazole, know under the generic name omeprazole. Further, the present invention also relates to the use of the novel crystalline form of 5–methoxy–2–[[(4–methoxy–3,5–dimethyl– 2–pyridinyl)methyl] sulfinyl]–1H– benzimidazole for the treatment of gastrointestinal disorders, pharmaceutical compositions containing it as well as processes for the preparation of the novel crystalline form of 5–methoxy–2–[[(4–methoxy–3,5–dimethyl– 2–pyridinyl)methyl] sulfinyl]–1H– benzimidazole.